Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic...

Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )

Enzalutamide improves survival in men with metastatic castration-resistant...

Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA

Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer ( Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA )

Latest treatment for CRPC: Combinations, sequencing, radiotherapy and...

Dr Maria De Santis - Kaiser Franz Josef Hospital, Vienna, Austria

Latest treatment for CRPC: Combinations, sequencing, radiotherapy and immunotherapy ( Dr Maria De Santis - Kaiser Franz Josef Hospital, Vienna, Austria )

Results of orteronel plus prednisone in the TAK-700 trial on mCRPC

Dr Robert Dreicer - Cleveland Clinic, Cleveland, USA

Results of orteronel plus prednisone in the TAK-700 trial on mCRPC ( Dr Robert Dreicer - Cleveland Clinic, Cleveland, USA )

Advances in prostate cancer - a decade in review

Dr Karim Fizazi, Dr Cora Sternberg, Dr John Fitzpatrick, Dr Heather Payne, Dr...

Advances in prostate cancer - a decade in review ( Dr Karim Fizazi, Dr Cora Sternberg, Dr John Fitzpatrick, Dr Heather Payne, Dr Peter Nelson )

Dissecting the biology of the androgen receptor pathway

Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA

Dissecting the biology of the androgen receptor pathway ( Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA )

Prostate Cancer Debate 2014: Evolving treatment options in castration-resistant...

Dr Cora Sternberg, Dr Marc Rubin, Dr Heather Payne, Dr Maria De Santis and Dr...

Prostate Cancer Debate 2014: Evolving treatment options in castration-resistant prostate cancer ( Dr Cora Sternberg, Dr Marc Rubin, Dr Heather Payne, Dr Maria De Santis and Dr John Fitzpatrick )

Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC)

Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Dublin...

Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC) ( Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Dublin, Ireland )

mCRPC: Challenges and opportunities in a booming area

Dr Nicolas Mottet - University Hospital, Saint-Étienne, France

mCRPC: Challenges and opportunities in a booming area ( Dr Nicolas Mottet - University Hospital, Saint-Étienne, France )

Predictors of response to mCRPC therapy: where do we stand?

Dr Ronald de Wit - Rotterdam Cancer Institute, Daniel den Hoed Cancer Center...

Predictors of response to mCRPC therapy: where do we stand? ( Dr Ronald de Wit - Rotterdam Cancer Institute, Daniel den Hoed Cancer Center, Netherlands )

Managing mCRPC in daily practice: a pragmatic approach

Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK

Managing mCRPC in daily practice: a pragmatic approach ( Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK )

Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel...

J.M. Fitzpatrick, N. Mottet, R. de Wit, Rotterdam and A Birtle

Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel discussion ( J.M. Fitzpatrick, N. Mottet, R. de Wit, Rotterdam and A Birtle )

More from ecancer